AbCellera Biologics (ABCL) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 122.4% versus a gain of 11.8%. AbCellera Biologics is the larger company by market cap ($3.95 billion vs $3.72 billion), about 1.1 times the size. Telix Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.9% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | TLX |
|---|---|---|
| Share price | $12.18 | $10.94 |
| Market cap | $3.95B | $3.72B |
| 1-day change | -5.07% | -1.62% |
| YTD return | +275.15% | +48.46% |
| 1-year return | +122.36% | +11.76% |
| 5-year return | -17.39% | — |
| P/E ratio (TTM) | — | 109.40 |
| EPS (TTM) | $-0.54 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $803.79M |
| Revenue growth (YoY) | +160.56% | +55.61% |
| Net income (latest FY) | $-146.41M | $-7.13M |
| Gross margin | — | 53.05% |
| Operating margin | -288.98% | 3.70% |
| Net margin | -194.88% | -0.89% |
| 52-week high | $15.02 | $13.11 |
| 52-week low | $2.75 | $6.28 |
| Distance from 52-week high | -18.88% | -16.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.11% | +86.65% |
| Average volume | 6.67M | 258.23K |
| Shares outstanding | 324.05M | 339.78M |
| Employees | 562 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed TLX by 110.6 percentage points over the past year.
- Telix Pharmaceuticals is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +55.61%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
ABCL vs TLX FAQ
Which is bigger, AbCellera Biologics or Telix Pharmaceuticals?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.95B compared with $3.72B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, ABCL or TLX?
ABCL returned +122.36% over the past 12 months, compared with +11.76% for TLX (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.